ArticleMedicine2025
Postoperative radiotherapy for stage pIIIA-N2 non-small cell lung cancer patients undergoing sublobar resection: A retrospective cohort study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study assesses the effect of postoperative radiotherapy on survival outcomes in patients diagnosed with stage pIIIA-N2 non-small cell lung cancer (NSCLC) after sublobar resection. Data of patients with stage pIIIA-N2 NSCLC who underwent sublobar resection were extracted from the Surveillance, Epidemiology, and End Results database spanning from 2000 to 2020. Patients were divided into 2 groups: postoperative radiotherapy and observation. Cancer-specific survival (CSS) and overall survival (OS) were analyzed and compared between the 2 groups. A total of 444 patients were included in the study, with 210 (47.3%) receiving postoperative radiotherapy and 234 (52.7%) with observation. The CSS (hazard ratio [HR] = 0.99, 95% confidence interval [CI]: 0.78-1.26; P = .926) and OS (HR = 0.93, 95% CI: 0.75-1.15; P = .512) did not show significant differences between the postoperative radiotherapy and observation groups. Subgroup analysis of patients receiving postoperative chemotherapy revealed comparable CSS (HR = 1.24, 95% CI: 0.89-1.71; P = .203) and OS (HR = 1.12, 95% CI: 0.85-1.49; P = .425) between the 2 groups. Similarly, for patients without postoperative chemotherapy, CSS (HR = 1.11, 95% CI: 0.66-1.84; P = .699) and OS (HR = 1.08, 95% CI: 0.68-1.71; P = .740) were not significantly different between the 2 groups. Postoperative radiotherapy does not improve survival in patients with stage pIIIA-N2 NSCLC following sublobar resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.